Apixaban versus other anticoagulants in patients with nonvalvular fibrillation: a comparison of all-cause and event-related costs in real-life setting in France

Manon Belhassen (), Olivier Hanon, Philippe Gabriel Steg, Isabelle Mahé, Mélanie Née, Flore Jacoud, Faustine Dalon, François-Emery Cotté, Dominique Guitard-Dehoux, Claire Marant-Micallef, Eric Van Ganse and Nicolas Danchin
Additional contact information
Manon Belhassen: PELyon
Olivier Hanon: Université de Paris, APHP Centre, Hôpital Broca
Philippe Gabriel Steg: Université de Paris, INSERM U-1148/LVTS, F ; Assistance Publique-Hôpitaux de Paris, Hôpital Bichat
Isabelle Mahé: Hôpital Louis Mourier, Université de Paris, Innovative Therapies in Haemostasis, INSERM
Mélanie Née: PELyon
Flore Jacoud: PELyon
Faustine Dalon: PELyon
François-Emery Cotté: Bristol-Myers Squibb
Dominique Guitard-Dehoux: Bristol-Myers Squibb
Claire Marant-Micallef: PELyon
Eric Van Ganse: PELyon
Nicolas Danchin: Hôpital Européen Georges Pompidou, Université de Paris

The European Journal of Health Economics, 2023, vol. 24, issue 6, No 2, 867-875

Abstract: Abstract Objectives Compare costs associated with all-cause healthcare resource use (HCRU), stroke/systemic thromboembolism (STE) and major bleedings (MB) between patients with non-valvular atrial fibrillation (NVAF) initiating apixaban or other oral anticoagulants (OACs). Methods We performed a retrospective cohort study using the French healthcare claims database, including NVAF patients between 2014/01/01 and 2016/12/31, followed until 2016/12/31. We used 4 sub-cohorts of OAC-naive patients, respectively initiating apixaban, dabigatran, rivaroxaban or VKAs. We matched patients initiating apixaban with patients initiating each other OACs using 1:n propensity score matching. All-cause HCRU and event-related costs by OAC treatment were estimated and compared between matched patients using generalised-linear models with gamma-distribution and two-part models. Results There were 175,766 patients in the apixaban–VKA, 181,809 in the apixaban–rivaroxaban, and 42,490 in the apixaban–dabigatran matched cohorts. Patients initiating apixaban had significantly lower HCRU costs than patients initiating VKA (€1,105 vs. €1,578, p

Keywords: Apixaban; Non-valvular atrial fibrillation; Costs; Anticoagulants (search for similar items in EconPapers)
Date: 2023
References: View references in EconPapers View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s10198-022-01513-2 Abstract (text/html)
Access to the full text of the articles in this series is restricted.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:eujhec:v:24:y:2023:i:6:d:10.1007_s10198-022-01513-2

Ordering information: This journal article can be ordered from
http://www.springer. ... cs/journal/10198/PS2

DOI: 10.1007/s10198-022-01513-2

Access Statistics for this article

The European Journal of Health Economics is currently edited by J.-M.G.v.d. Schulenburg

More articles in The European Journal of Health Economics from Springer, Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ) Contact information at EDIRC.
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().